

Alzheimer's Diseases: Towards Biomarkers for an Early Diagnosis

Benaïssa Elmoualij¹, Ingrid Dupiereux¹, Jérémie Seguin², Isabelle Quadrio²,
Willy Zorzi¹, Armand Perret-Liaudet² and Ernst Heinen¹

¹*Department of Human Histology-CRPP, University of Liège, Sart Tilman, Liège*

²*Department Maladies à Prions, Service de Neurobiologie, CBPE, Hôpitaux de Lyon*

¹*Belgium*

²*France*

1. Introduction

Alzheimer's diseases (AD) are the most frequent dementias across the world and represent more than 60% of all neurodegenerative dementias including those with Lewy bodies (DLB) and frontotemporal lobar degeneration (FTLD). Most neurodegenerative dementias are induced by aggregation of different brain proteins; they are nosologically grouped into a large pathological entity named proteinopathy. Prevalence of dementias is more than 20% in 85 years old aged population and linearly increases with the age (Ferri, Prince et al. 2005). The international impact of degenerative dementias across the world is estimated to touch more than 24 million patients with an incidence about 4.6 million new cases by year.

Diagnosis of AD is still based on the integration of clinical examination, neuropsychological data, radiological and biological analyses. The final diagnosis is established after neuropathological examination of brain and observation of typical cerebral failures, in consequence, the clinical diagnosis is "probable AD" when typical criteria are found and "possible AD" if atypical elements are present during clinical examination. Nevertheless, the clinical diagnosis performance for "probable AD" is relatively low with a sensitivity and a specificity of 80% and 70% respectively (Knopman, DeKosky et al. 2001). Because a consequent clinical overlap does exist between etiological AD and others causes of dementia, the clinical diagnosis specificity for a possible AD is less than 50%. Paraclinical analyses such as radiological and biological examinations tend to increase accuracy of differential diagnoses as well as diagnosis precocity for these patients.

2. How can we deal with the clinical diversity of Alzheimer's phenotypes?

AD is associated with a progressive disruption of the neuronal function and subsequent gradual deterioration in cognition and behaviour leading finally to the death (Khachaturian, 1985). The typical clinical beginning of AD is characterised by a progressive cognitive alteration affecting predominantly episodic memory. Other symptoms such as language deficit, visuoperceptive alterations or even dysexecutive syndromes appear during the course of the disease in relation to the progression of cerebral failures into the associative brain areas. Decrease in episodic memory is associated with radiological finding of obvious

medial temporal lobe atrophy during the first step of the disease progression (Scheltens, Fox et al. 2002). Effectively, this cerebral structure highly participates in the memory process; even more, neuropathological findings demonstrated the strong implication of typical protein depositions met in AD that occur during this medial temporal lobe atrophy (Burton, Barber et al. 2009). Nevertheless, this kind of atrophy can be met in other pathologies such as FTLN or DLN, without any cerebral pathological hallmark of AD (O'Brien, Paling et al. 2001; van de Pol, Hensel et al. 2006). Moreover, frequent clinical overlaps (Kertesz, McMonagle et al. 2005; Josephs, Petersen et al. 2006; Hort, O'Brien et al. 2010) as well as pathological co-occurrence (Merdes, Hansen et al. 2003; Amador-Ortiz, Lin et al. 2007; Schneider, Arvanitakis et al. 2009) between these 3 dementias can occur, resulting in a misleading clinical diagnosis during lifetime.

During the AD progression, other symptoms than the alteration of the episodic memory progressively appear, but they can also be clinically predominant at the first step of the disease. For example, a dysexecutive syndrome, concordant with a frontal atrophy, and then the first hypothesis of frontotemporal dementia (FTD) diagnosis can finally be an AD. As well, an aphasic clinical presentation associated with temporal cerebral areas atrophy, suggestive of primary progressive aphasia, can reveal an etiological AD. Other clinical presentations can occur in the first symptoms of AD, such as apraxic forms suggesting corticobasal degeneration (CBD) or even visual deficits associated with posterior cortical atrophy (PCA).

These focal presentations of AD are clinically difficult to distinguish from other previously adverted neurodegenerative dementias which typically begin with these kind of clinical features (Alladi, Xuereb et al. 2007). It is why there is a need to identify inside this spectrum focal presentations underlying AD as well as other pathologic processes such as FTLN or DLN.

3. Neuropathological hallmark and physiopathological pathways of AD

The two neuropathological hallmarks of AD are the deposition of extracellular amyloid plaques and accumulation of intracellular neurofibrillary tangles (NFT). The first ones are principally constituted by amyloid protein ($A\beta$ peptide), a product of proteolytic processing by secretases of the amyloid precursor protein named APP (Haass and Selkoe 1993), and the second involves phosphorylated tau protein (Masters, Simms et al. 1985; Braak and Braak 1991). Distributions of amyloid plaques and NFTs do not overlap in all anatomical regions suggesting a complex pathogenetic scenario.

Tau protein is a microtubule associated protein expressed abundantly in the neuronal axons that promotes assembly and stability of microtubules. 6 different isoforms of tau are present in the human brain, constituted of 352 to 441 amino acids and harbouring more than 70 phosphorylation sites (Buée, Bussiere et al. 2000; Lewczuk, Esselmann et al. 2004). Its physiological function is regulated by these phosphorylations (Johnson and Hartigan 1999). The abnormal hyperphosphorylation of tau proteins in AD brain reduces their biological activity and results in disintegration of the microtubules (Uversky, Winter et al. 1998). Moreover, this phenomenon induces conformational changes of tau protein and then permits its assembly in paired helical filaments (PHF), the major constituent of NFTs (Kidd 1963; Alonso, Zaidi et al. 2001). These PHF are highly phosphorylated since more than 30 phosphorylation sites were observed in PHF deriving from NFTs (Liu, Liang et al. 2006). The stereotypic development of tau pathology with NFTs is clearly correlated with clinical

impairment of memory, starting in the transentorhinal cortex to finally involve associative areas and the whole neocortical areas (Braak and Braak 1995; Berg, McKeel et al. 1998).

In an other scheme, A β depositions neither correlate with a given clinical presentation and seem to begin in the neocortex before involving the neuronal projections of already involved areas (Arriagada, Growdon et al. 1992). These amyloid plaques are also encountered in asymptomatic aged peoples without AD (Wolf, Gearing et al. 1999). Furthermore, metabolic imaging and particularly positron emission tomography with ^{11}C -PIB (a compound that specifically stain amyloid plaques) demonstrate that these amyloid accumulations are observed in subjects without any cognitive alteration (Villemagne, Fodero-Tavoletti et al. 2008). Although numerous proteins are associated with amyloid deposits in AD (Buée, Hof et al. 1992; Uchihara, Duyckaerts et al. 1996; Burns, Noble et al. 2003), the major proteinaceous component is the 42 amino acid A β peptide (A β ₄₂) which is the most hydrophobic form of A β (Jarrett, Berger et al. 1993; Gravina, Ho et al. 1995). Nevertheless, it was recently demonstrated that aggregation into amyloid plaques may provide truncated forms of this peptide in the N-terminal (A β _{4-5-/8-/9-42}) during the first steps of the disease (Sergeant, Bombois et al. 2003; Vanderstichele, De Meyer et al. 2005). These truncated forms could represent more than 60% of all cerebral A β forms (Sergeant, Bombois et al. 2003).

Interestingly, the symptomatology observed in AD (or other neurodegenerative dementia) seems not due to these deposits and symptoms could appear before protein aggregations (Moechars, Dewachter et al. 1999). Several *in vitro* studies demonstrated that the toxicity against neurons is related to oligomeric forms of proteins and that the consequence is cognitive alteration in animal models (Kirkitadze, Bitan et al. 2002; Cleary, Walsh et al. 2005; Lesne, Koh et al. 2006). For AD, soluble oligomeric forms have been described, aggregating later on into amyloid plaques and it was suggested that effects of these oligomeric species could induce the first toxic events of amyloidopathy (Simmons, May et al. 1994; Kirkitadze, Condrón et al. 2001; Walsh and Selkoe 2007).

Some controversy still remains on the course and distribution pattern of the A β and tau pathologies. Some authors suggest that amyloid dysfunction is the pathogenic key leading to AD pathogenesis. This hypothesis was developed as "amyloid cascade" and the A β metabolism dysfunction may initiate others pathologic events such as tau protein hyperphosphorylation, synaptic loss or neuroinflammation (Hardy and Higgins 1992; Hardy and Selkoe 2002). Nevertheless this hypothesis is still discussed and does not support all the AD physiopathology.

During the preclinical phase of AD, the neuronal degeneration proceeds and at a certain, yet unidentified, threshold the first symptoms appear. Otherwise, it seems that first cerebral failures begin several decades before symptoms appear (Braak and Braak 1997). Nevertheless the early and differential diagnosis remains difficult and reliable proof of AD process is difficult to obtain. An early and reliable diagnosis in order to establish appropriate drug treatment is essential to decrease symptomatology. Moreover, since research is conducted to develop treatments that could retard or stop cerebral failure progression, we need to improve AD diagnosis to identify this process before brain damages are too significant.

4. Which CSF biochemical markers might allow us to detect Alzheimer's diseases?

It is convincing that we could identify these neurodegenerative processes early during the course of AD with the help of paraclinical means such as functional imaging or use of biological markers.

An ideal biomarker for Alzheimer disease would have to meet three specific criteria:

- To be a quantitative and objective measure providing an indication of disease risk and rate of disease progression long before onset of symptoms
- To be reliable, reproducible and inexpensive to measure
- To be measurable in an easily accessible tissue of the patient.

During the past years, great efforts have been made to identify reliable biomarkers for AD in body fluids of patients that are suitable for minimal invasive early diagnosis of AD, mainly cerebrospinal fluid (CSF) and blood. Cerebrospinal fluid (CSF) closely reflects the composition of the brain extracellular space and is likely to have the highest yield in biomarkers (Wiltfang, Lewczuk et al. 2005). Furthermore, CSF biological modifications seem to appear before first anatomical modifications seen on magnetic resonance imaging (Schoonenboom, van der Flier et al. 2008). Nevertheless, lumbar puncture is relatively invasive even if complications appear in less than 2% of patients (Blennow, Wallin et al. 1993). So research strives for a less invasive biological diagnosis with development of blood markers for AD.

A high number of CSF brain-derived proteins have been investigated as potential markers for AD. The more promising are proteins resulting from cerebral failures meet in AD: tau proteins with total tau (T-tau), phosphorylated tau proteins (P-tau) and A β ₄₂ which are solubles in CSF. Moreover, AD diagnosis criteria were reviewed for research in 2007 and these 3 biomarkers were included (Dubois, Feldman et al. 2007).

- A β peptide

In AD patients the CSF concentration of soluble A β ₄₂ decreases and it has been suggested that this may be due to the preferential deposition of A β peptides into cerebral amyloid plaques reflecting parenchymal sequestration with lower levels diffusing to CSF (Strozyk, Blennow et al. 2003; Wiltfang, Lewczuk et al. 2005; Fagan, Mintun et al. 2006). Interestingly, this CSF concentration is linked to ApoE genotype which was identified as a susceptibility gene to develop AD: patients with homozygote genotype of ApoE4 have lower A β ₄₂ CSF concentration (Galasko, Chang et al. 1998). Nevertheless, a CSF A β ₄₂ concentration decrease is also observed in other pathologies such as DLB or even Creutzfeldt Jakob disease (CJD), pathology with sometimes cerebral A β deposits (Andreasen, Minthon et al. 2001; Wiltfang, Esselmann et al. 2003; Mollenhauer, Bibl et al. 2005). These results are in accordance with pathological overlaps observed in these diseases (Schneider, Arvanitakis et al. 2007; Schneider, Arvanitakis et al. 2009; Kovacs, Seguin et al. 2011). Nonetheless, measurement of CSF A β ₄₂ concentration could differentiate AD patients from subjects without any neurodegenerative process with sensitivity and specificity of 86% and about 90% respectively (Blennow 2004). ELISA measurement of CSF A β ₄₂ reveals values comprised between 600 and 1230 pg/mL in normal subjects and 260 and 500 pg/mL in AD patients (Riemenschneider, Lautenschlager et al. 2002; Riemenschneider, Wagenpfeil et al. 2002; Lewczuk, Esselmann et al. 2004).

Several works postulate that A β aggregates will be more reliable biomarkers than soluble A β forms, as the aggregates are directly involved in the pathologic events of AD. Monoclonal and polyclonal antibodies specific to soluble oligomeric forms of A β were developed (Kayed et al, 2010, Ying Z et al, 2009) and used to demonstrate that these oligomers are significantly more abundant in the soluble brain extracts of AD patients (Meli et al., 2009) suggesting that diffusible oligomers would also appear in the CSF. Sensitive techniques were applied to detect CSF A β oligomers in AD patients (Pitschke, Prior et al. 1998). Recently, a study showed that levels of CSF aggregated A β forms are higher in AD

patients than in patients with other neurological disorders without neurodegenerative processes (Fukumoto, Tokuda et al. 2010). Moreover, the CSF oligomer concentrations correlate with cognitive alteration in AD. While detection of these CSF oligomeric forms appears to have a considerable diagnosis interest, low concentrations of these pathologic forms do not allow considering this assay routinely?.

In parallel to A β ₄₂, numerous N- and C- terminal truncated forms have been identified in clinical samples from AD patients (Gabelle, Roche et al. 2010). Most abundant A β peptides in CSF are, in increasing order concentrations, A β ₄₀, A β ₃₈ and A β ₄₂ (Wiltfang, Esselmann et al. 2002). Concentration measurements of the major form A β ₄₀ in CSF are greatly instructive because they well reflect total amount of A β peptide release in this biological fluid (Wiltfang, Esselmann et al. 2007). By the APP metabolism and the amyloidogenic way, strong cerebral producers of A β peptides have higher A β CSF levels (and thus also A β ₄₂) than weak producers. Instauration of A β ₄₀ CSF measurements associated with A β ₄₂ could permit to rectify mistakes in interpretation of biological results with CSF A β ₄₂ levels alone.

In addition to CSF A β ₄₀, A β ₃₈ and A β ₄₂, other forms of this peptide are produced by physiological regulation of γ -secretase (Gabelle, Roche et al. 2010). Numerous both cerebral and CSF truncated forms of A β peptide were identified in AD and MCI patients using immunoblotting or mass spectrometry analyses (such as SELDI-TOF) (Lewczuk, Esselmann et al. 2003; Sergeant, Bombois et al. 2003; Vanderstichele, De Meyer et al. 2005). Part of research concentrates on identification of novel A β truncated forms that could allow better predictive power and specificity of biological diagnosis (Bibl, Mollenhauer et al. 2007). Indeed, new A β ₁₃, A β ₁₄ or else A β ₁₆ peptides were described within CSF of AD patients and surprisingly A β ₁₆ CSF levels increase in AD patients (Portelius, Zetterberg et al. 2006). Identification of these A β fragments in the CSF could lead to a more specific differential diagnosis since it may exist distinct CSF A β fragment profiles between AD, DLB or FTD, these profiles could reflect distinct physiopathological events between these pathologies (Bibl, Mollenhauer et al. 2007). So, the use of these new biomarkers could lead to novel diagnostics and therapeutics approaches for Alzheimer's diseases.

- Tau proteins

Increase of T-tau CSF levels was found in AD patients as well as MCI patients who will develop later an AD (Riemenschneider, Buch et al. 1996; Andreasen, Minthon et al. 2001; Riemenschneider, Lautenschlager et al. 2002; Hansson, Zetterberg et al. 2006). Measurement of T-tau levels with ELISA test (Innotest hTau Ag, Innogenetics) reveal concentrations between 150 pg/mL and 450 pg/mL in control subjects and between 300 and 1100 pg/mL in AD patients (Riemenschneider, Lautenschlager et al. 2002; Lewczuk, Esselmann et al. 2004; Grossman, Farmer et al. 2005). Nevertheless, increase of T-tau CSF levels is not AD specific since it is also observed in different concentrations in CJD or even an acute stroke (Otto, Wiltfang et al. 1997; Hesse, Rosengren et al. 2000). T-tau CSF levels in patients with sporadic CJD are higher than those observed in patients with other neurodegenerative dementias including AD (Otto, Wiltfang et al. 1997; Otto, Wiltfang et al. 2002). Threshold for CSF T-tau concentration in sporadic CJD was determined at 1300pg/mL in 2002 in a study conducted on 300 patients with CJD with 109 neuropathological confirmations (Otto, Wiltfang et al. 2002). In other forms of CJD as new variant, CSF T-tau levels are lower than those observed in sporadic disease (Sanchez-Juan, Green et al. 2006). Thus, T-tau is more a neuronal death marker than a specific AD biomarker. Several diseases are neuropathologically linked to tau dysfunction such as in some FTD, progressive supranuclear palsy (PSP) and CBD. Numerous studies have investigated measurement of CSF T-tau levels in FTD but results are

in accordance with pathological heterogeneity of FTD (neuropathological tau inclusions or without tau inclusions) since existence of discordance between studies with increase of CSF T-tau levels or not (Riemenschneider, Wagenpfeil et al. 2002; Pijnenburg, Schoonenboom et al. 2004; Grossman, Farmer et al. 2005). Any biological argument does exist with T-tau CSF levels in pathologies like FTD or other tauopathies as PSP and CBD (Urakami, Wada et al. 2001). Interestingly, a distinct profile of T-tau in electrophoretic separation was observed in CSF of sporadic CJD patients in a very recent study (Chen, Shi et al. 2010).

More interestingly, some modifications as truncated forms can be identified on tau proteins. A recent study permitted to demonstrate differences in CSF levels of truncated forms of tau in PSP patients compared with other neurodegenerative diseases (FTD, CBD, AD, DLB and Parkinson disease) or control subjects (Borroni, Gardoni et al. 2009). Other proteolytic processes on tau protein can occur in neurodegenerative disorders and could be identified.

CSF P-tau level specifically increase in AD patients compared with those with FTD, vascular dementia or control subjects (Hampel, Buerger et al. 2004). Regarding DLB, results are more conflicting with studies describing increase of P-tau CSF levels and others reporting normal concentrations (Vanmechelen, Vanderstichele et al. 2000; Parnetti, Lanari et al. 2001). So, an increase in P-tau CSF levels is observed in AD and MCI patients (Itoh, Arai et al. 2001; Andreasen, Vanmechelen et al. 2003; Herukka, Hallikainen et al. 2005). Moreover, cognitive decline is correlated with CSF increasing levels of P-tau, these CSF tau species might specifically mark a cerebral degenerative process (Maccioni, Lavados et al. 2006; Wallin, Blennow et al. 2006). While other P-tau species have been measured, only CSF levels of tau proteins phosphorylated at serine 181 (P-tau₁₈₁) or threonine 231 (P-tau₂₃₁) seem to clearly improve the accuracy of the diagnostic of AD (Buerger, Zinkowski et al. 2002; Hampel and Teipel 2004; Mitchell 2009). Some phosphorylations are more specific for AD, CSF P-tau₁₈₁ significantly increases in AD patients compared to patients without neurodegenerative processes as well as patients with other neurodegenerative dementias (Vanmechelen, Vanderstichele et al. 2000; Vanderstichele, De Vreese et al. 2006). The P-tau₁₈₁ assay in CSF is now routinely used for biological differential diagnosis between AD and other forms of dementias. ELISA measurements of this protein (Innotest phospho-tau_(181P), Innogenetics) reveal CSF levels between 30 pg/mL and 50 pg/mL in control subjects and between 75 pg/mL and 100 pg/mL in AD patients (Lewczuk, Esselmann et al. 2004). This phosphorylated form of tau protein permits to distinguish an AD from all other neurodegenerative etiologies with great sensitivity and specificity (Hampel, Buerger et al. 2004). P-tau₁₈₁ CSF measurement is able to differentiate AD patients from FTD patients with a sensitivity of 85% and a specificity more than 80% (Schoonenboom, Pijnenburg et al. 2004). These results are similar in differentiation of AD and all other neurodegenerative dementias (Hampel, Buerger et al. 2004). Furthermore this measurement improves distinction of AD and DLB patients (Parnetti, Lanari et al. 2001; Vanderstichele, De Vreese et al. 2006).

Other phosphorylated species of tau protein allow to improve accuracy of biological diagnosis. The P-tau₂₃₁ appears early during AD pathogenesis (Augustinack, Schneider et al. 2002). This form of tau in CSF differentiates patients with AD from control subject with high sensitivity and specificity (more than 90%) (Mitchell 2009), nevertheless its interest for differential diagnosis appears to be less important than P-tau₁₈₁ except for distinction of AD and FTD (Hampel, Buerger et al. 2004). Moreover P-tau₂₃₁ well reflects AD neuropathology because its CSF concentration is correlated with amounts of NFT found at the autopsy (Buerger, Ewers et al. 2006). Since this form of phosphorylated tau permits to identify AD within a population of patients presenting a mild cognitive impairment (MCI), it seems

particularly interesting for the early diagnosis (Brys, Pirraglia et al. 2009). The CSF P-tau₂₃₁ levels decrease with time during the AD process; this will enable to approach dementia severity (Hampel, Buerger et al. 2001). CSF P-tau₁₉₉ measurement and determination of its phosphorylation, that seems precociously involved during AD pathogenesis and NFT formation (Maurage, Sergeant et al. 2003), are able to discriminate AD patients from other degenerative dementias with a sensitivity and a specificity of 85% and 80% respectively (Itoh, Arai et al. 2001). Phosphorylation of tau protein on both amino acid 231 and 235 might be predictive of MCI conversion into AD (Arai, Ishiguro et al. 2000). In the same way, CSF level of P-tau_{396/404} is elevated in AD compared to vascular dementia, and control subjects (Hu, He et al. 2002). Nevertheless these results have to be confirmed on patients with other degenerative disorders.

- Combination of etiological markers

The use of combinations of these CSF markers (A β ₄₂, T-tau and P-tau₁₈₁) improves biological diagnosis performance for dementias in terms of differential or early diagnosis (Andreasen, Minthon et al. 2001; Riemenschneider, Wagenpfeil et al. 2002; Pijnenburg, Schoonenboom et al. 2004). These CSF biomarkers are also prognosis markers since a recent prospective study conduct on 150 AD patients for 5 years revealed that extreme CSF biomarkers levels (high T-tau and P-tau₁₈₁ and low A β ₄₂) are associated with more aggressive diseases leading to an earlier death (Wallin, Blennow et al. 2010).

Recently, a clinical study of the Alzheimer Disease Neuroimaging Initiative Project has detected an Alzheimer disease signature in the CSF levels of, A β ₄₂ T-tau and P-tau₁₈₁ in more than one third of cognitively normal subjects (De Meyer, Shapiro et al. 2010). This finding suggests that this CSF signature is present and detectable early during the neurodegenerative process. A recent study including 43 patients with a clinical dementia disorder and conducted in Sweden failed to show a concordance between T-tau and A β CSF levels and pathological symptoms (Brunnstrom, Rawshani et al. 2010). Further, it has been suggested that low CSF A β ₄₂ may also be a marker of diffuse plaques in addition to fibrillar plaques. Indeed, Fagan and colleagues have studied the relationship between *in vivo* brain amyloid and CSF markers of proteins (T-tau, P-tau₁₈₁ and A β ₄₂) in cognitively normal individuals ranging in age from 43-89 years (Fagan, Mintun et al. 2009). In this study they have identified a new class of non demented individuals who present low CSF A β ₄₂ with cerebral amyloid deposition. The authors suggested that CSF A β ₄₂ drop prior to amyloid becomes detectable and may reflect the presence of diffuse plaques and/or oligomeric A β species. These data demonstrate that CSF A β ₄₂ may be considered as a biomarker for plaque burden and prognosis providing the very earliest clue to identify preclinical AD.

Combination of CSF T-tau and A β ₄₂ allows to distinguish AD from FTD patients with both sensitivity and specificity of 85% (Riemenschneider, Wagenpfeil et al. 2002). Moreover the use of this combination permits to identify AD in MCI patients with sensitivity and specificity of 95% and 83% respectively (Hansson, Zetterberg et al. 2006). Interestingly, predictive value of P-tau₁₈₁ is better than T-tau for prediction of conversion of MCI in AD patients (Parnetti, Lanari et al. 2006). Association of 3 biomarkers is clearly useful to identify a degenerative process concordant with AD in atypical clinical presentation. A study with 9 patients presenting PCA revealed CSF levels of these 3 biomarkers similar to those observed in AD (Baumann, Duyar et al. 2010). In the same way, very recent prospective study conducted on 22 ACP patients demonstrated that a majority of patients with this syndrome (90%) have intrathecal biomarker levels compatible with AD (Seguin, Formaglio et al. in press).

Using of ratio T-tau/ $A\beta_{42}$ increases the diagnosis specificity of AD compared with control subjects and other degenerative dementias (Gomez-Tortosa, Gonzalo et al. 2003; Kapaki, Paraskevas et al. 2003). Specificity of this ratio in differentiation of AD from vascular dementias is higher than 80% nevertheless this ratio is less efficient for differentiating AD and DLB (Gomez-Tortosa, Gonzalo et al. 2003). Finally, ratio T-tau/ $A\beta_{42}$ could be early instructive since its increase permits to predict cognitive alterations in asymptomatic subjects within 8 years (Fagan, Roe et al. 2007). Similarly, the ratio P-tau₁₈₁/ $A\beta_{42}$ appears as an important element for differential diagnosis. It allows to distinguish AD patients from those with FTD with a sensitivity and a specificity of more than 90% (de Souza, Lamari et al. 2010). Furthermore this ratio is able to discriminate patients with semantic dementia from AD patients with an excellent sensitivity of 98% and a specificity of 84%. Ratios with other forms of $A\beta$ peptides such as $A\beta_{42}/A\beta_{38}$ and $A\beta_{42}/A\beta_{37}$ combined with T-tau CSF levels are able to differentiate AD from DLB with a sensitivity of 100% and a specificity of 92% (Bibl, Mollenhauer et al. 2006).

Since CSF T-tau levels in sporadic CJD are clearly elevated comparing to all other neurodegenerative disorders and P-tau₁₈₁ is in normal concentrations, the use of P-tau₁₈₁/T-tau ratio seems interesting to identify CJD patients (Riemenschneider, Wagenpfeil et al. 2003). This ratio is inferior to 0.05 in CJD and superior to 1.25 in AD even in very early stages of the disease. Similar results were found with P-tau₂₃₁/T-tau (Buerger, Otto et al. 2006). It is important to note that CSF P-tau₁₈₁ level in new variant CJD are higher than in sporadic CJD, and this inversely to T-tau CSF level (Goodall, Head et al. 2006). So, this ratio P-tau₁₈₁/T-tau is able to differentiate sporadic CJD from new variant with an elevated ratio. Nevertheless, biological levels overlap, particularly between new variant CJD and AD, thus does not permit to attain a differential diagnosis value.

Other combinations with different P-tau are useful for biological diagnosis. Combining CSF P-tau₁₈₁ and P-tau₂₃₁ enables to identify AD patients with a sensitivity of 94%, but a weak specificity of 66% confronting with all neurodegenerative disorders (Hampel, Buerger et al. 2004). More interestingly, ratio of P-tau_{396/404} and T-tau is able to distinguish AD patients from others dementias with a sensitivity and a specificity of 96% and 86% respectively and have an excellent specificity (100%) in the distinction of AD and vascular dementias (Hu, He et al. 2002).

- Others potential biological markers

Numerous other molecules have been investigated as biological CSF markers and are liable to participate on etiological dementia diagnosis. We briefly deal with some of them which seem to supply advantage for differential and early diagnosis.

Implication of oxidative stress hypothesis and inflammation in AD or other neurodegenerative disorders opened some research ways. It is known that inflammation is associated with parenchymal $A\beta$ deposits in AD (Schmidt, Schmidt et al. 2002). Inflammation markers have been investigated in CSF to reveal potential inflammatory process linked to these pathological deposits. Inflammatory mediators such as chemokines might be increased into AD patients CSF (Galimberti, Schoonenboom et al. 2006; Galimberti, Schoonenboom et al. 2006). The concentration of classical complement cascade C1q subunit decreases in CSF of AD patients and is correlated with disease severity (Smyth, Cribbs et al. 1994). However, this intrathecal molecule only attests for microglial reactions met in AD and also during physiological aging (Lue, Walker et al. 2001; Schuitmaker, van der Doef et al. 2011). Similarly isoprostane CSF levels, an oxidative stress marker, clearly increase in biological fluid (CSF, blood and urine) proportionally to cognitive decline and might be an

early biomarker of AD in MCI patients (Pratico, Clark et al. 2000; Pratico, Clark et al. 2002). If these molecules seem interesting for understanding physiopathological mechanisms which occur in neurodegenerative disorders (oxidative stress and microglial activation particularly), these biomarkers cannot be a specific part of differential diagnosis since they are frequently involved during cerebral aging (Montine, Peskind et al. 2011).

Molecules with an implication in protein catabolism are present within CSF and their levels may reflect cerebral damages. An increase of the intrathecal neprisylin activity was observed and correlated to T-tau CSF level and cognitive decline in AD patients and patient with prodromal form of AD (Maruyama, Higuchi et al. 2005). Nevertheless this activity is modestly predictive for MCI conversion to dementia. Ubiquitine, another catabolic signal protein might be linked to aggregated tau proteins in the cerebral cortex and its CSF levels might increase in AD patients (Iqbal, Flory et al. 2005). Moreover ubiquitine CSF levels correlate with those linked with cerebral tau aggregates in AD (Kudo, Iqbal et al. 1994). Nevertheless, elevated ubiquitine CSF levels were observed in other non-AD dementias (Iqbal and Grundke-Iqbal 1997).

A protein largely present in CSF and blood, transthyretin, has higher CSF levels in AD and MCI stage. CSF measurements can distinguish AD from control subjects with sensitivity of 100% and specificity of 93% (Lovell, Lynn et al. 2008). In the same way, CSF concentrations of the mitochondrial protein cytochrome c are increased in AD and permit to identify AD process in MCI patients with a sensitivity of 100% and specificity of 75% (Papaliagkas, Anogianakis et al. 2009). However, a specificity problem is present regarding other neurodegenerative dementia such as FTD (Ruetschi, Zetterberg et al. 2005).

Recently, Zhong and colleagues have quantified the levels and the activity in the CSF of β -secretase (BACE 1), an enzyme involved in the cleavage of APP to A β (Zhong, Ewers et al. 2007). An elevated BACE 1 activity was observed in CSF of MCI and AD subjects compared with normal controls. Moreover, this activity was correlated with CSF BACE 1 protein and A β peptide levels. A more recent study showed that CSF BACE1 activity correlates with CSF A β_{40} , total T-tau and P-tau₁₈₁ levels but surprisingly not with intrathecal A β_{42} concentration (Mulder, van der Flier et al. 2010). These results are promising and suggest that BACE 1 could be a potential candidate as a biomarker of early-stage AD, but additional studies are necessary to confirm this hypothesis.

4. Peripheral biomarkers

Because the CSF collection by lumbar puncture is an invasive, expensive and time-consuming procedure, the detection of biomarker molecules in blood would be more widely applicable. However, in comparison with CSF biomarkers, efforts to discover reliable biomarkers for Alzheimer's disease in peripheral blood have not been successful and do not allow developing a solid diagnostic. The use of many different sensitive ELISA tests for the detection of A β_{40} and A β_{42} allowed the detection and quantification of A β in human plasma (for review see Irizarry, 2004; Mehta, 2007). According to these studies, some controversy persists concerning the changes in blood A β levels in relation with the severity of the disease suggesting that plasma A β levels cannot allow differentiating sporadic AD from control cases. As the pool of circulating A β includes multiple C-terminal truncated fragments, and possibly oligomeric species, it has been suggested that the use of antibodies to various forms of A β with different affinities may explain these differences. Nevertheless, the ELISA assay may not be an ideal method to measure A β levels in blood. Indeed, the two major

difficulties in the measurement of A β in plasma consist in the low concentration of the plasma peptide, needing a more sensitive quantification assay, and in the interaction of the beta peptide with different carrier proteins present in plasma, that can mask the epitopes of A β and interfere with the detection of the peptide (Kuo et al., 2000).

Nowadays, the development of more sensitive and more specific assays for the detection of plasma A β levels is needed for proposing plasma A β as a biomarker for diagnosis. To overcome the A β low levels different new promising strategies have been developed based on purification and concentration steps prior to the A β peptides analysis. Using a denaturing solid-phase extraction (SPE) combined with an ELISA assay, Lanz and co-workers (Lanz & Schachter, 2008) have compared the A β detection in plasma and CSF biofluids of normal individuals. But, while human CSF exhibit, in comparison with non-SPE samples, the most robust recovery ($\geq 90\%$), the human plasma showed a lower recovery (between 40 and 60% in function of the extraction process used, guanidine or acid formic, respectively) suggesting that the use of a SPE step does not improve the detection of the protein comparatively to the non-denatured plasma. Slemmon and collaborators (Slemmon et al., 2007) have linked to the SPE a reverse-phase HPLC (SPE-HPLC) compatible with analysis by ELISA. In this study, the detection of A β peptides from the whole blood of six normal subjects was analyzed; by comparison with a native plasma, a significantly increase in the amount of total A β peptide was obtained after guanidine extraction and HPLC detection, with concentrations ranging from 100 to 165pg/ml. These results suggest that there is a pool of A β peptides in non-denatured plasma samples that is not accessible for the detection by ELISA assay probably due to their interactions with plasma proteins or to their aggregated state that could mask the epitopes.

Several studies on the detection of tau proteins in blood have been performed but failed to show a clear relationship to dementia diagnosis, thus, the correlation between increased tau brain levels and elevated CSF levels of tau in AD patients is not totally clear (Bitsch et al., 2002; Ingelson et al., 1999). Further research is needed to improve the specificity and the sensitivity of the assay in order to develop a robust method to measure tau protein levels in serum or plasma.

Recently, various plasma signalling proteins were proposed as potential candidates to develop a blood test for AD (Ray et al., 2007). O'Bryant and colleagues developed an algorithm in order to differentiate patients with Alzheimer disease from controls. In this study serum protein-based multiplex biomarker data from a large group of Alzheimer patients and controls were analyzed. Combined with age, sex, years of education and ApoE genotype, their logarithm model reached a diagnostic sensitivity and specificity of 94% and 84% respectively (O'Bryant et al., 2010).

In addition to CSF and blood, several other biological fluids are under investigation for the detection of AD biomarkers. Among these biological fluids, a special attention is accorded to saliva and urine. The study of Bermejo and colleagues (Bermejo-Pareja et al., 2010) found that saliva A β_{42} is, in comparison with control subjects, significantly elevated in early stage AD patients while A β_{40} levels remain unchanged within all the samples analyzed. Curiously the elevated saliva A β_{42} levels were not observed in severe stages of the disease. This augmentation seems to be specific to AD and not to Parkinson disease. These results show that in combination with A β levels in brain, the saliva levels of A β_{42} could be a potential biomarker for clinical AD.

In addition to the specific markers of AD disease (like A β peptides and tau proteins), there are non-specific markers like oxidative stress and neuronal inflammation molecules. An increased expression in AD patients of many inflammatory and pro-inflammatory cytokines has been widely documented. Inflammation in AD brains induces important microglia

activation and consequently production of free radicals responsible of an intense oxidative stress. So these inflammatory and oxidative mechanisms are involved in the aetiology of AD and can contribute to the neurodegeneration. However conflicting results exist about the pertinence of the use of these peripheral biomarkers. Among the inflammatory markers several cytokines have been measured in CSF or blood, such as interleukin 1- α and 1- β , interleukin-6, -10, -11 and -18, and tumor necrosis factor- α (for review see Casoli et al., 2010; Olson & Humpel, 2010). But the results are very divergent between the different groups. The same conclusions can be enunciated for chemokines. More studies are needed to clarify and determine the reproducibility of such inflammatory markers.

Oxidative stress parameters have also been investigated as AD biomarker. A biomarker of oxidative stress study (BOSS) coordinated by the NIH was performed in order to determine among 16 commonly studied biochemical products of oxidative stress which ones could be validated as *in vivo* biomarkers (kadiiska et al., 2005). This study was performed on plasma, blood and urine samples. Among these molecules, malondialdehyde (MDA), 8-hydroxy-2'-deoxyguanosine (8-OHdG) and F2-isopranes were the most promising biomarkers of oxidative stress. F2-isopranes, a product of lipid peroxidation, was the most extensively investigated in CSF of AD patients. These clinical studies showed comparatively with control subjects a significant increase of F2-isopranes in damaged regions of AD brain and in CSF in patients in early stages of mild cognitive dementia (Montine et al., 1999, 2001; Pratico et al., 2000). In plasma and urine samples, the quantification of such marker yield to conflicting results.

5. Which techniques could be applied?

Hyperphosphorylated Tau proteins are currently used for AD diagnostics in CSF, as recently proposed by an international working group on Alzheimer Disease (NINCDS-ADRA working group) (Dubois et al., 2007). Moreover, there are no well-established and accepted biochemical tests available for therapeutic follow-up of these diseases. Their diagnosis requires thus high sensitivity and specificity. Sensitivity is needed for early diagnosis, when the biomarker is present at very low levels to ensure cost-effective therapeutic interventions before the disease has progressed to a stage where damages to the brain are irreversible. Specificity is needed to discriminate first, non-degenerative causes of dementia (e.g. vascular, alcoholic, psychiatric, metabolic, infective etc.) from degenerative forms and, second, to discriminate the different molecular aetiologies in order to propose an appropriate therapeutic treatment: for example, anticholinesterase drugs show certain efficacy in AD, but not in frontotemporal dementia (Musial et al., 2007).

Today, AD can be diagnosed with certainty only post-mortem with histopathological evaluation of amyloid plaques and NFTs. Ante-mortem, AD is diagnosed by clinical criteria. Clinical diagnosis included systematically before 2007 December the presence of dementia (McKhann et al., 1984). Before apparition of dementia symptoms, complaining patients suffer from memory trouble without social and professional effects; this clinical phase was usually called "amnesic mild cognitive impairment (MCI)" (Petersen et al., 1999). Many of these patients convert to AD whereas few of them convert to other neurodegenerative dementia or remain stable (Fischer et al., 2007). As recently proposed, using the combination of clinical, neuropsychological, imaging methods and CSF biomarkers, this clinical stage would be nowadays called preclinical AD and, more important, its detection would allow a better care for AD patients. Neuropsychological evaluation permits a more accurately defined diagnosis, but it is time consuming (half a day), is not available for all concerned

people, is still proposed at advanced stages of disease, and is not 100% accurate since there is a risk of overlaps among different aetiologies of dementia as frontotemporal degeneration (FTD), Lewy's body dementia (LBD), and potentially other dementias. Neuroimaging may permit exclusion of vascular pathology, detection of hippocampal atrophy and cerebral hypoperfusion (Tapiola et al., 2008; Xu et al., 2007). It must be noted that first AD lesions may coexist with vascular dementia in at least 50 % of cases. During the past years, great efforts have been made to identify reliable biomarkers for AD in body fluids of patients that are suitable for minimal invasive early diagnosis of AD, mainly cerebrospinal fluid (CSF) and blood. Recently, we've summarized all of the criteria needed to establish convenient technique with the following advantages (Dupiereux et al. (2009):

- a. Low-cost
- b. Rapid-fast
- c. Good level of accuracy

6. Should Alzheimer's detection be associated to biomarkers of other diseases?

Other diseases could be associated with AD resulting in mixed dementias. Furthermore, unique pathologies could mimic others and it is difficult to make differences between given pathological events or to identify all neurodegenerative processes. Effectively, 15 to 50% of AD patients have Lewy bodies (neuropathological hallmark of DLB constituted by α -synuclein) associated with NFT and A β deposits after neuropathological examination (Hamilton 2000). Nevertheless, α -synuclein (α -Syn) is not always associated with this clinical phenotype (Parkkinen, Kauppinen et al. 2005). This pathological association seems to make part for cognitive alteration severity with a synergic effect (Clinton, Blurton-Jones et al. 2010). Mixed dementia may be more aggressive than pure AD (Kraybill, Larson et al. 2005). Since a low CSF α -Syn level was detected in CSF of patients with DLB and Parkinson disease comparing to other neurodegenerative diseases, an association of this measurement with typical CSF biomarkers of AD seems interesting (Tokuda, Salem et al. 2006; Kasuga, Tokutake et al. 2010). Moreover, oligomeric forms of α -Syn were detected in CSF and blood of patients with Parkinson disease (El-Agnaf, Salem et al. 2006). Nevertheless, several studies are conflicting since elevated or normal CSF levels were also observed in DLB patients (Mukaetova-Ladinska, Milne et al. 2008; Spies, Melis et al. 2009; Ballard, Jones et al. 2010). In the same way, we can postulate an association of typical CSF biomarkers of AD with prion CSF measurement since neuropathology of CJD is more intricate than we thought it several years ago (Kovacs, Seguin et al. 2011).

7. Acknowledgments

This work was financially supported by the Région Wallonne, contract BA4 grant 114915, contract EPH331030000092-430001, Fonds Social Européen contract W2002134, contract 14531, iPCRq, and Neuroscreen LSHB-CT-2006-037719 contract n° 037719.

8. References

Alladi, S., J. Xuereb, et al. (2007). "Focal cortical presentations of Alzheimer's disease." *Brain* 130(Pt 10): 2636-45.

- Alonso, A., T. Zaidi, et al. (2001). "Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments." *Proc Natl Acad Sci U S A* 98(12): 6923-8.
- Amador-Ortiz, C., W. L. Lin, et al. (2007). "TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease." *Ann Neurol* 61(5): 435-45.
- Andreasen, N., L. Minthon, et al. (2001). "Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice." *Arch Neurol* 58(3): 373-9.
- Andreasen, N., E. Vanmechelen, et al. (2003). "Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment." *Acta Neurol Scand Suppl* 179: 47-51.
- Arai, H., K. Ishiguro, et al. (2000). "CSF phosphorylated tau protein and mild cognitive impairment: a prospective study." *Exp Neurol* 166(1): 201-3.
- Arriagada, P. V., J. H. Growdon, et al. (1992). "Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease." *Neurology* 42(3 Pt 1): 631-9.
- Augustinack, J. C., A. Schneider, et al. (2002). "Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease." *Acta Neuropathol (Berl)* 103(1): 26-35.
- Ballard, C., E. L. Jones, et al. (2010). "alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies." *Int Psychogeriatr* 22(2): 321-7.
- Baumann, T. P., H. Duyar, et al. (2010). "CSF-Tau and CSF-Abeta(1-42) in Posterior Cortical Atrophy." *Dement Geriatr Cogn Disord* 29(6): 530-533.
- Berg, L., D. W. McKeel, Jr., et al. (1998). "Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype." *Arch Neurol* 55(3): 326-35.
- Bermejo-Pareja, F.; Antequera, D.; Vargas, T.; Molina, J.A. & Carro, E. (2010). Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. *BMC Neurol.*, Vol.3, No.10, pp. 108
- Bibl, M., B. Mollenhauer, et al. (2006). "CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies." *J Neural Transm* 113(11): 1771-8.
- Bibl, M., B. Mollenhauer, et al. (2007). "Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias." *Mol Psychiatry*.
- Bitsch, A.; Horn, C.; Kemmling, Y.; Seipelt, M.; Hellenbrand, U.; Stiefel, M.; Ciesielczyk, B.; Cepek, L.; Bahn, E.; Ratzka, P.; Prange, H. & Otto, M. (2002). Serum tau protein level as a marker of axonal damage in acute ischemic stroke. *Eur Neurol.*, Vol.47, No.1, pp. 45-51
- Blennow, K. (2004). "Cerebrospinal fluid protein biomarkers for Alzheimer's disease." *NeuroRx* 1(2): 213-25.
- Blennow, K., A. Wallin, et al. (1993). "Low frequency of post-lumbar puncture headache in demented patients." *Acta Neurol Scand* 88(3): 221-3.
- Borroni, B., F. Gardoni, et al. (2009). "Pattern of Tau forms in CSF is altered in progressive supranuclear palsy." *Neurobiol Aging* 30(1): 34-40.
- Braak, H. and E. Braak (1991). "Neuropathological staging of Alzheimer-related changes." *Acta Neuropathol (Berl)* 82(4): 239-59.

- Braak, H. and E. Braak (1995). "Staging of Alzheimer's disease-related neurofibrillary changes." *Neurobiol Aging* 16(3): 271-8; discussion 278-84.
- Braak, H. and E. Braak (1997). "Frequency of stages of Alzheimer-related lesions in different age categories." *Neurobiol Aging* 18(4): 351-7.
- Brunnstrom, H., N. Rawshani, et al. (2010). "Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses." *Alzheimers Dement* 6(2): 104-9.
- Brys, M., E. Pirraglia, et al. (2009). "Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment." *Neurobiol Aging* 30(5): 682-90.
- Buée, L., T. Bussiere, et al. (2000). "Tau protein isoforms, phosphorylation and role in neurodegenerative disorders." *Brain Res Brain Res Rev* 33(1): 95-130.
- Buée, L., P. R. Hof, et al. (1992). "Immunohistochemical identification of thrombospondin in normal human brain and in Alzheimer's disease." *Am J Pathol* 141(4): 783-8.
- Buerger, K., M. Ewers, et al. (2006). "CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease." *Brain* 129(Pt 11): 3035-41.
- Buerger, K., M. Otto, et al. (2006). "Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease." *Neurobiol Aging* 27(1): 10-5.
- Buerger, K., R. Zinkowski, et al. (2002). "Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231." *Arch Neurol* 59(8): 1267-72.
- Burns, M. P., W. J. Noble, et al. (2003). "Co-localization of cholesterol, apolipoprotein E and fibrillar Aβ in amyloid plaques." *Brain Res Mol Brain Res* 110(1): 119-25.
- Burton, E. J., R. Barber, et al. (2009). "Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis." *Brain* 132(Pt 1): 195-203.
- Casoli, T.; Di Stefano, G.; Baliotti, M.; Solazzi, M.; Giorgetti, B. & Fattoretti, P. (2010). Peripheral inflammatory biomarkers of Alzheimer's disease: the role of platelets. *Biogerontology*, Vol.11, No.5, pp. 627-633
- Chen, C., Q. Shi, et al. (2010). "The prepared tau exon-specific antibodies revealed distinct profiles of tau in CSF of the patients with Creutzfeldt-Jakob disease." *PLoS One* 5(7): e11886.
- Cleary, J. P., D. M. Walsh, et al. (2005). "Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function." *Nat Neurosci* 8(1): 79-84.
- Clinton, L. K., M. Blurton-Jones, et al. (2010). "Synergistic Interactions between Aβ, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline." *J Neurosci* 30(21): 7281-9.
- De Meyer, G., F. Shapiro, et al. (2010). "Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people." *Arch Neurol* 67(8): 949-56.
- de Souza, L. C., F. Lamari, et al. (2010). "Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias." *J Neurol Neurosurg Psychiatry*.
- Dubois, B.; Feldman, H. H.; Jacova, C.; Dekosky, S. T.; Barberger-Gateau, P.; Cummings, J.; Delacourte, A.; Galasko, D.; Gauthier, S.; Jicha, G.; Meguro, K.; O'Brien, J.; Pasquier, F.; Robert, P.; Rossor, M.; Salloway, S.; Stern, Y.; Visser, P. J. & Scheltens, P. (2007).

- Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol.*, Vol.6, No.8, pp. 734-746
- Dubois, B., H. H. Feldman, et al. (2007). "Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria." *Lancet Neurol* 6(8): 734-46.
- Dupiereux I, W, Quadrio I, Perret-Liaudet A, Kovacs GG, Heinen E, ElMoualij B. (2009). "Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer diseases: from diagnosis to therapy". *Current Medical Chemistry-Central Nervous System Agents*. 9, 2-11.
- El-Agnaf, O. M., S. A. Salem, et al. (2006). "Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease." *Faseb J* 20(3): 419-25.
- Fagan, A. M., M. A. Mintun, et al. (2006). "Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans." *Ann Neurol* 59(3): 512-9.
- Fagan, A. M., M. A. Mintun, et al. (2009). "Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease." *EMBO Mol Med* 1(8-9): 371-80.
- Fagan, A. M., C. M. Roe, et al. (2007). "Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults." *Arch Neurol* 64(3): 343-9.
- Ferri, C. P., M. Prince, et al. (2005). "Global prevalence of dementia: a Delphi consensus study." *Lancet* 366(9503): 2112-7.
- Fischer, P.; Jungwirth, S.; Zehetmayer, S.; Weissgram, S.; Hoenigschnabl, S.; Gelpi, E.; Krampla, W. & Tragl, K. H. (2007). Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. *Neurology*, Vol.68, No.4, pp. 288-291
- Fukumoto, H., T. Tokuda, et al. (2010). "High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients." *Faseb J* 24(8): 2716-26.
- Gabelle, A., S. Roche, et al. (2010). "Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid." *Brain Res* 1357: 175-83.
- Galasko, D., L. Chang, et al. (1998). "High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype." *Arch Neurol* 55(7): 937-45.
- Galimberti, D., N. Schoonenboom, et al. (2006). "Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease." *Arch Neurol* 63(4): 538-43.
- Galimberti, D., N. Schoonenboom, et al. (2006). "Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration." *Neurology* 66(1): 146-7.
- Gomez-Tortosa, E., I. Gonzalo, et al. (2003). "Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease." *Arch Neurol* 60(9): 1218-22.
- Goodall, C. A., M. W. Head, et al. (2006). "Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications." *J Neurol Neurosurg Psychiatry* 77(1): 89-91.
- Gravina, S. A., L. Ho, et al. (1995). "Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43)." *J Biol Chem* 270(13): 7013-6.
- Grossman, M., J. Farmer, et al. (2005). "Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease." *Ann Neurol* 57(5): 721-9.

- Haass, C. and D. J. Selkoe (1993). "Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide." *Cell* 75(6): 1039-42.
- Hamilton, R. L. (2000). "Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry." *Brain Pathol* 10(3): 378-84.
- Hampel, H., K. Buerger, et al. (2001). "Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231." *Ann Neurol* 49(4): 545-6.
- Hampel, H., K. Buerger, et al. (2004). "Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study." *Arch Gen Psychiatry* 61(1): 95-102.
- Hampel, H. and S. J. Teipel (2004). "Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia." *Dement Geriatr Cogn Disord* 17(4): 350-4.
- Hansson, O., H. Zetterberg, et al. (2006). "Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study." *Lancet Neurol* 5(3): 228-34.
- Hardy, J. and D. J. Selkoe (2002). "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics." *Science* 297(5580): 353-6.
- Hardy, J. A. and G. A. Higgins (1992). "Alzheimer's disease: the amyloid cascade hypothesis." *Science* 256(5054): 184-5.
- Herukka, S. K., M. Hallikainen, et al. (2005). "CSF Aβ₄₂ and tau or phosphorylated tau and prediction of progressive mild cognitive impairment." *Neurology* 64(7): 1294-7.
- Hesse, C., L. Rosengren, et al. (2000). "Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke." *J Alzheimers Dis* 2(3-4): 199-206.
- Hort, J., J. T. O'Brien, et al. (2010). "EFNS guidelines for the diagnosis and management of Alzheimer's disease." *Eur J Neurol* 17(10): 1236-48.
- Hu, Y. Y., S. S. He, et al. (2002). "Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay." *Am J Pathol* 160(4): 1269-78.
- Ingelsson, M.; Blomberg, M.; Benedikz, E.; Wahlund, L.O.; Karlsson, E.; Vanmechelen, E. & Lannfelt, L. (1999). Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. *Dement Geriatr Cogn Disord.*, Vol.10, No.6, pp. 442-445
- Iqbal, K., M. Flory, et al. (2005). "Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers." *Ann Neurol* 58(5): 748-57.
- Iqbal, K. and I. Grundke-Iqbal (1997). "Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease." *Int Psychogeriatr* 9 Suppl 1: 289-96; discussion 317-21.
- Irizarry, M. C. (2004). Biomarkers of Alzheimer disease in plasma. *NeuroRx.*, Vol.1, No.2, pp. 226-234
- Itoh, N., H. Arai, et al. (2001). "Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease." *Ann Neurol* 50(2): 150-6.
- Jarrett, J. T., E. P. Berger, et al. (1993). "The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease." *Biochemistry* 32(18): 4693-7.

- Johnson, G. V. and J. A. Hartigan (1999). "Tau protein in normal and Alzheimer's disease brain: an update." *J Alzheimers Dis* 1(4-5): 329-51.
- Josephs, K. A., R. C. Petersen, et al. (2006). "Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP." *Neurology* 66(1): 41-8.
- Kadiiska, M.B.; Gladen, B.C.; Baird, D.D.; Germolec, D.; Graham, L.B.; Parker, C.E.; Nyska, A.; Wachsman, J.T.; Ames, B.N.; Basu, S.; Brot, N.; Fitzgerald, G.A.; Floyd, R.A.; George, M.; Heinecke, J.W.; Hatch, G.E.; Hensley, K.; Lawson, J.A.; Marnett, L.J.; Morrow, J.D.; Murray, D.M.; Plastaras, J.; Roberts, L.J.; Rokach, J.; Shigenaga, M.K.; Sohal, R.S.; Sun, J.; Tice, R.R.; Van Thiel, D.H.; Wellner, D.; Walter, P.B.; Tomer, K.B.; Mason, R.P. & Barrett, J.C. (2005). Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? *Free Radic Biol Med.*, Vol.38, No.6, pp. 698-710
- Kapaki, E., G. P. Paraskevas, et al. (2003). "CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population." *Eur J Neurol* 10(2): 119-28.
- Kasuga, K., T. Tokutake, et al. (2010). "Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease." *J Neurol Neurosurg Psychiatry* 81(6): 608-10.
- Kayed R, Canto I, Breydo L, Rasool S, Lukacovich T, Wu J, Albay R 3rd, Pensalfini A, Yeung S, Head E, Marsh JL, Glabe C, Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar A β oligomers, *Mol Neurodegener* 2010.
- Kertesz, A., P. McMonagle, et al. (2005). "The evolution and pathology of frontotemporal dementia." *Brain* 128(Pt 9): 1996-2005.
- Khachaturian, Z. S. (1985). Diagnosis of Alzheimer's disease. *Arch. Neurol*, Vol.42, No.11, pp. 1097-1105
- Kidd, M. (1963). "Paired helical filaments in electron microscopy of Alzheimer's disease." *Nature* 197: 192-3.
- Kirkitadze, M. D., G. Bitan, et al. (2002). "Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies." *J Neurosci Res* 69(5): 567-77.
- Kirkitadze, M. D., M. M. Condrón, et al. (2001). "Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis." *J Mol Biol* 312(5): 1103-19.
- Knopman, D. S., S. T. DeKosky, et al. (2001). "Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology." *Neurology* 56(9): 1143-53.
- Kovacs, G. G., J. Seguin, et al. (2011). "Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy." *Acta Neuropathol* 121(1): 39-57.
- Kraybill, M. L., E. B. Larson, et al. (2005). "Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both." *Neurology* 64(12): 2069-73.
- Kudo, T., K. Iqbal, et al. (1994). "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels." *Brain Res* 639(1): 1-7.
- Kuo, Y. M.; Kokjohn, T. A.; Kalback, W.; Luehrs, D.; Galasko, D. R.; Chevallier, N.; Koo, E. H.; Emmerling, M. R. & Roher, A. E. (2000). Amyloid-beta peptides interact with

- plasma proteins and erythrocytes: implications for their quantitation in plasma. *Biochem. Biophys. Res. Commun.*, Vol.268, No.3, pp. 750-756
- Lanz, T. A. & Schachter, J. B. (2008). Solid-phase extraction enhances detection of beta amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies. *J. Neurosci. Methods*, Vol.169, No.1, pp. 16-22
- Lesne, S., M. T. Koh, et al. (2006). "A specific amyloid-beta protein assembly in the brain impairs memory." *Nature* 440(7082): 352-7.
- Lewczuk, P., H. Esselmann, et al. (2004). "Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature." *J Mol Neurosci* 23(1-2): 115-22.
- Lewczuk, P., H. Esselmann, et al. (2003). "The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide." *Rapid Commun Mass Spectrom* 17(12): 1291-6.
- Lewczuk, P., H. Esselmann, et al. (2004). "Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau." *Neurobiol Aging* 25(3): 273-81.
- Liu, F., Z. Liang, et al. (2006). "Hyperphosphorylation of tau and protein phosphatases in Alzheimer disease." *Panminerva Med* 48(2): 97-108.
- Lovell, M. A., B. C. Lynn, et al. (2008). "An aberrant protein complex in CSF as a biomarker of Alzheimer disease." *Neurology* 70(23): 2212-8.
- Lue, L. F., D. G. Walker, et al. (2001). "Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures." *Neurobiol Aging* 22(6): 945-56.
- Maccioni, R. B., M. Lavados, et al. (2006). "Anomalous phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects." *Neurobiol Aging* 27(2): 237-44.
- Maruyama, M., M. Higuchi, et al. (2005). "Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease." *Ann Neurol* 57(6): 832-42.
- Masters, C. L., G. Simms, et al. (1985). "Amyloid plaque core protein in Alzheimer disease and Down syndrome." *Proc Natl Acad Sci U S A* 82(12): 4245-9.
- Maurage, C. A., N. Sergeant, et al. (2003). "Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology." *Acta Neuropathol (Berl)* 105(2): 89-97.
- McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D. & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*, Vol.34, No.7, pp. 939-944
- Mehta, P. D. (2007). Amyloid beta protein as a marker or risk factor of Alzheimer's disease. *Curr. Alzheimer Res.*, Vol.4, No.4, pp. 359-363
- Meli, G, Visintin M, Cannistraci I, Cattaneo A, Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers, *J Mol Biol* 2009.
- Merdes, A. R., L. A. Hansen, et al. (2003). "Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies." *Neurology* 60(10): 1586-90.
- Mitchell, A. J. (2009). "CSF Phosphorylated Tau in the Diagnosis and Prognosis of Mild Cognitive Impairment and Alzheimer's Disease - A Meta-analysis of 51 Studies." *J Neurol Neurosurg Psychiatry*.

- Moechars, D., I. Dewachter, et al. (1999). "Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain." *J Biol Chem* 274(10): 6483-92.
- Mollenhauer, B., M. Bibl, et al. (2005). "Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease." *J Neural Transm* 112(7): 933-48.
- Montine, T.J.; Beal, M.F.; Cudkowicz, M.E.; O'Donnell, H.; Margolin, R.A.; McFarland, L.; Bachrach, A.F.; Zackert, W.E.; Roberts, L.J. & Morrow, J.D. (1999). Increased CSF F2-isoprostane concentration in probable AD. *Neurology*, Vol.52, No.3, pp. 562-565
- Montine, T.J.; Kaye, J.A.; Montine, K.S.; McFarland, L.; Morrow, J.D. & Quinn, J.F. (2001). Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. *Arch Pathol Lab Med.*, Vol.125, No.4, pp. 510-512
- Montine, T. J., E. R. Peskind, et al. (2011). "Increased Cerebrospinal Fluid F(2)-Isoprostanes are Associated with Aging and Latent Alzheimer's Disease as Identified by Biomarkers." *Neuromolecular Med* 13(1): 37-43.
- Mukaetova-Ladinska, E. B., J. Milne, et al. (2008). "Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes." *Dement Geriatr Cogn Disord* 26(1): 32-42.
- Mulder, S. D., W. M. van der Flier, et al. (2010). "BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology." *J Alzheimers Dis* 20(1): 253-60.
- Musial, A.; Bajda, M. & Malawska, B. (2007). Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. *Curr. Med. Chem.*, Vol.14, No.25, pp. 2654-2679
- O'Brien, J. T., S. Paling, et al. (2001). "Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia." *Neurology* 56(10): 1386-8.
- O'Bryant, S.E.; Xiao, G.; Barber, R.; Reisch, J.; Doody, R.; Fairchild, T.; Adams, P.; Waring, S. & Diaz-Arrastia, R. (2010). A serum protein-based algorithm for the detection of Alzheimer disease. *Arch Neurol.*, Vol.67, No.9, pp. 1077-81
- Olson, L. & Humpel, C. (2010). Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. *Exp Gerontol.*, Vol.45, No.1, pp. 41-46
- Otto, M., J. Wiltfang, et al. (2002). "Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease." *Neurology* 58(2): 192-7.
- Otto, M., J. Wiltfang, et al. (1997). "Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease." *Neurosci Lett* 225(3): 210-2.
- Papaliagkas, V. T., G. Anogianakis, et al. (2009). "Prediction of conversion from mild cognitive impairment to Alzheimer's disease by CSF cytochrome c levels and N200 latency." *Curr Alzheimer Res* 6(3): 279-84.
- Parkkinen, L., T. Kauppinen, et al. (2005). "Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia." *Ann Neurol* 57(1): 82-91.
- Parnetti, L., A. Lanari, et al. (2001). "CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group." *Neurol Sci* 22(1): 77-8.

- Parnetti, L., A. Lanari, et al. (2006). "Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers." *Mech Ageing Dev* 127(2): 129-32.
- Petersen, R. C.; Smith, G. E.; Waring, S. C.; Ivnik, R. J.; Tangalos, E. G. & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. *Arch. Neurol.*, Vol.56, No.3, pp. 303-308
- Pijnenburg, Y. A., N. S. Schoonenboom, et al. (2004). "CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration." *Neurology* 62(9): 1649.
- Pitschke, M., R. Prior, et al. (1998). "Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy." *Nat Med* 4(7): 832-4.
- Portelius, E., H. Zetterberg, et al. (2006). "An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid." *Neurosci Lett* 409(3): 215-9.
- Pratico, D., C. M. Clark, et al. (2000). "Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity." *Ann Neurol* 48(5): 809-12.
- Pratico, D., C. M. Clark, et al. (2002). "Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease." *Arch Neurol* 59(6): 972-6.
- Ray, S.; Britschgi, M.; Herbert, C.; Takeda-Uchimura, Y.; Boxer, A.; Blennow, K.; Friedman, L. F.; Galasko, D. R.; Jutel, M.; Karydas, A.; Kaye, J. A.; Leszek, J.; Miller, B. L.; Minthon, L.; Quinn, J. F.; Rabinovici, G. D.; Robinson, W. H.; Sabbagh, M. N.; So, Y. T.; Sparks, D. L.; Tabaton, M.; Tinklenberg, J.; Yesavage, J. A.; Tibshirani, R. & Wyss-Coray, T. (2007). Classification and prediction of clinical Alzheimer's diagnosis based on plasma signalling proteins. *Nat. Med.*, Vol.13, No.11, pp. 1359-1362
- Riemenschneider, M., K. Buch, et al. (1996). "Cerebrospinal protein tau is elevated in early Alzheimer's disease." *Neurosci Lett* 212(3): 209-11.
- Riemenschneider, M., N. Lautenschlager, et al. (2002). "Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment." *Arch Neurol* 59(11): 1729-34.
- Riemenschneider, M., S. Wagenpfeil, et al. (2002). "Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration." *Neurology* 58(11): 1622-8.
- Riemenschneider, M., S. Wagenpfeil, et al. (2003). "Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias." *Mol Psychiatry* 8(3): 343-7.
- Ruetschi, U., H. Zetterberg, et al. (2005). "Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF." *Exp Neurol* 196(2): 273-81.
- Sanchez-Juan, P., A. Green, et al. (2006). "CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease." *Neurology* 67(4): 637-43.
- Scheltens, P., N. Fox, et al. (2002). "Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion." *Lancet Neurol* 1(1): 13-21.
- Schmidt, R., H. Schmidt, et al. (2002). "Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study." *Ann Neurol* 52(2): 168-74.
- Schneider, J. A., Z. Arvanitakis, et al. (2007). "Mixed brain pathologies account for most dementia cases in community-dwelling older persons." *Neurology* 69(24): 2197-204.
- Schneider, J. A., Z. Arvanitakis, et al. (2009). "The neuropathology of probable Alzheimer disease and mild cognitive impairment." *Ann Neurol* 66(2): 200-8.

- Schoonenboom, N. S., Y. A. Pijnenburg, et al. (2004). "Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease." *Neurology* 62(9): 1580-4.
- Schoonenboom, N. S., W. M. van der Flier, et al. (2008). "CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease." *Neurobiol Aging* 29(5): 669-75.
- Schuitmaker, A., T. F. van der Doef, et al. (2011). "Microglial activation in healthy aging." *Neurobiol Aging*.
- Seguin, J., M. Formaglio, et al. (in press). "Cerebrospinal Fluid biomarkers in posterior cortical atrophy." *Neurology*.
- Sergeant, N., S. Bombois, et al. (2003). "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach." *J Neurochem* 85(6): 1581-91.
- Simmons, L. K., P. C. May, et al. (1994). "Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro." *Mol Pharmacol* 45(3): 373-9.
- Slemmon, J. R.; Painter, C. L.; Nadanaciva, S.; Catana, F.; Cook, A.; Motter, R. & Seubert, P. (2007). Distribution of Abeta peptide in whole blood. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.*, Vol.846, No.1-2, pp. 24-31
- Smyth, M. D., D. H. Cribbs, et al. (1994). "Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state." *Neurobiol Aging* 15(5): 609-14.
- Spies, P. E., R. J. Melis, et al. (2009). "Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders." *J Alzheimers Dis* 16(2): 363-9.
- Strozyk, D., K. Blennow, et al. (2003). "CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study." *Neurology* 60(4): 652-6.
- Tapiola, T.; Pennanen, C.; Tapiola, M.; Tervo, S.; Kivipelto, M.; Hanninen, T.; Pihlajamaki, M.; Laakso, M. P.; Hallikainen, M.; Hamalainen, A.; Vanhanen, M.; Helkala, E. L.; Vanninen, R.; Nissinen, A.; Rossi, R.; Frisoni, G. B. & Soininen, H. (2008). MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. *Neurobiol. Aging*, Vol.29, No.1, pp. 31-38
- Tokuda, T., S. A. Salem, et al. (2006). "Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease." *Biochem Biophys Res Commun* 349(1): 162-6.
- Uchihara, T., C. Duyckaerts, et al. (1996). "Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease." *Acta Neuropathol* 92(2): 180-5.
- Urakami, K., K. Wada, et al. (2001). "Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy." *J Neurol Sci* 183(1): 95-8.
- Uversky, V. N., S. Winter, et al. (1998). "Hyperphosphorylation induces structural modification of tau-protein." *FEBS Lett* 439(1-2): 21-5.
- van de Pol, L. A., A. Hensel, et al. (2006). "Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease." *J Neurol Neurosurg Psychiatry* 77(4): 439-42.

- Vanderstichele, H., G. De Meyer, et al. (2005). "Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment." *Clin Chem* 51(9): 1650-60.
- Vanderstichele, H., K. De Vreese, et al. (2006). "Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies." *Clin Chem Lab Med* 44(12): 1472-80.
- Vanmechelen, E., H. Vanderstichele, et al. (2000). "Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization." *Neurosci Lett* 285(1): 49-52.
- Villemagne, V. L., M. T. Fodero-Tavoletti, et al. (2008). "The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias." *Mol Neurobiol* 38(1): 1-15.
- Ying Z, Xin W, Jin-Sheng H, Fu-Xiang B, Wei-Min S, Xin-Xian D, Xiao-Bo W, Yi-Qin L, Xian-Xian Z, Hong-Gang H, Xiang-Lei P, Yan-Peng Z, Ling-Ling H, Tao H, Preparation and characterization of a monoclonal antibody with high affinity for soluble Abeta oligomers, Hybridoma (Larchmt) 2009))
- Wallin, A. K., K. Blennow, et al. (2006). "CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival." *Dement Geriatr Cogn Disord* 21(3): 131-8.
- Wallin, A. K., K. Blennow, et al. (2010). "CSF biomarkers predict a more malignant outcome in Alzheimer disease." *Neurology* 74(19): 1531-7.
- Walsh, D. M. and D. J. Selkoe (2007). "Abeta Oligomers - a decade of discovery." *J Neurochem*.
- Wiltfang, J., H. Esselmann, et al. (2007). "Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load." *J Neurochem* 101(4): 1053-9.
- Wiltfang, J., H. Esselmann, et al. (2002). "Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation." *J Neurochem* 81(3): 481-96.
- Wiltfang, J., H. Esselmann, et al. (2003). "Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease." *Ann Neurol* 54(2): 263-7.
- Wiltfang, J., P. Lewczuk, et al. (2005). "Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia." *World J Biol Psychiatry* 6(2): 69-84.
- Wolf, D. S., M. Gearing, et al. (1999). "Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study." *Alzheimer Dis Assoc Disord* 13(4): 226-31.
- Xu, G.; Antuono, P. G.; Jones, J.; Xu, Y.; Wu, G.; Ward, D. & Li, S. J. (2007). Perfusion fMRI detects deficits in regional CBF during memory-encoding tasks in MCI subjects. *Neurology*, Vol. 69, No. 17, pp. 1650-1656
- Zhong, Z., M. Ewers, et al. (2007). "Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment." *Arch Gen Psychiatry* 64(6): 718-26.